Is Investing in ASX Small Cap Healthcare Stocks a Lucrative Proposition?

Investors usually gravitate towards Top ASX Healthcare Stocks. What even astute investors forget is that healthcare industry offers small cap stocks with a well defined business model that can be very lucrative, albeit with a larger time horizon. Some small cap stocks with innovative solutions offer great potential in the long run. 

Orthocell Limited (ASX: OCC)

Orthocell Limited is gaining momentum in the global medical device market, particularly with its leading products, Striate+ and Remplir. Striate+, which focuses on dental bone and tissue regeneration, has been bolstered by a global license and manufacturing agreement with BioHorizons, a major player in the dental industry. This partnership, which includes AU$21.5 million in upfront cash and an exclusive licensing deal, validates Striate+ and the CelGro Platform, opening doors to the largest healthcare markets and significantly reducing execution risk. 

It also supports the scale-up of manufacturing to meet the anticipated growth in purchase orders from BioHorizons and provides access to a global distribution network through Meanwhile, Remplir, a nerve repair product, is showing impressive clinical outcomes and generating revenue in Australia and New Zealand. Orthocell is strategically positioning itself for global expansion with these approvals and a robust product portfolio.

Orthocell’s FY24 revenue reached $6.76 million, reflecting a 30.76% increase from FY23’s $5.17 million, driven by strong sales in its core products. 

Orthocell is one of the Best LongTerm Healthcare Stocks as its business is propelled by its innovative collagen-based products that address critical needs in medical fields. Orthocell’s future growth is anchored on two major product developments. First, the anticipated US approval for Remplir in early 2025, which could open up the world’s largest market for peripheral nerve repair, where over 700,000 procedures are conducted annually. Striate+ is also expected to see strong revenue growth as it expands into new markets like Brazil and Singapore.

Orthocell Limited is emerging as among top ASX Healthcare Companies in the medical device industry, with its innovative products, Striate+ and Remplir, driving revenue growth. These products have strong potential, especially with upcoming regulatory approvals that could open up larger markets. The company is financially stable, with no debt and good distribution partnerships, positioning it well to capture a significant share of the nerve and dental repair markets.

Immutep Limited (ASX: IMM)

Immutep Limited, on 14 August 2024, reported that the first patient had been successfully dosed in the first-inhuman Phase I trial of IMP761.

Immutep Limited had earlier reported positive results from its final discussions with the FDA regarding the planned TACTI-004 Phase III trial of eftilagimod alfa (“efti”) in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, and histology-based platinum doublet chemotherapy for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC), regardless of PD-L1 expression. This lays a strong foundation for the development of an effective treatment for non-squamous and squamous 1L NSCLC patients who have high, low, or no PD-L1 expression and are eligible for anti-PD-1 therapy.

On 17 July 2024, IMM received regulatory clearance to initiate the first-in-human Phase I study of IMP761. The study is expected to enrol first participant during Q3 CY2024.

As of June 30, 2024, Immutep reported a robust cash and cash equivalent balance of approximately A$161.8 million, supplemented by a A$20 million bank term deposit, bringing the total cash position to A$181.8 million. This financial strength provides an expected cash runway into late 2026.

There is a significant multi-billion-dollar market opportunity for Efti similar to that currently enjoyed by KEYTRUDA in metastatic non-small cell lung cancer (NSCLC). The NSCLC drug market is estimated at US$ 24 billion, positioning Efti to potentially capture a substantial share of this highly profitable market. Additionally, in head and neck squamous cell carcinoma (HNSCC), where the drug market is valued at US$ 3 billion, Efti's FDA Fast Track designation accelerates its path toward approval, signaling the potential for rapid market entry.

Source: Company’s Report